Research progress on the clinical features and mechanisms of COVID-19 combined with liver injury
The highly contagious novel coronavirus pneumonia (COVID-19) that broke out in December 2019 has brought huge threats and losses to human society, so it has been the concern of every countries government. Presently, there are no specific drugs for COVID-19; however, a variety of potentially effective antiviral drugs, vaccines, cell therapies, traditional Chinese medicine and other methods are in clinical trials. Liver injury is a common complication of patients receiving COVID-19 treatment and its possible high incidence may affect the outcome of the disease. The pathogenesis of COVID-19 combined with liver injury in existing studies is still unclear, and relevant guidelines and expert consensuses are insufficient for clinical diagnosis and treatment. Therefore, the relevant progress and issues are now reviewed here.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology - 28(2020), 6 vom: 20. Juni, Seite 523-527 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Xie, Y B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 16.07.2020 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3760/cma.j.cn501113-20200416-00190 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312368232 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312368232 | ||
| 003 | DE-627 | ||
| 005 | 20231225144252.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3760/cma.j.cn501113-20200416-00190 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1041.xml |
| 035 | |a (DE-627)NLM312368232 | ||
| 035 | |a (NLM)32660185 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Xie, Y B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Research progress on the clinical features and mechanisms of COVID-19 combined with liver injury |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.07.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The highly contagious novel coronavirus pneumonia (COVID-19) that broke out in December 2019 has brought huge threats and losses to human society, so it has been the concern of every countries government. Presently, there are no specific drugs for COVID-19; however, a variety of potentially effective antiviral drugs, vaccines, cell therapies, traditional Chinese medicine and other methods are in clinical trials. Liver injury is a common complication of patients receiving COVID-19 treatment and its possible high incidence may affect the outcome of the disease. The pathogenesis of COVID-19 combined with liver injury in existing studies is still unclear, and relevant guidelines and expert consensuses are insufficient for clinical diagnosis and treatment. Therefore, the relevant progress and issues are now reviewed here | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Liver injury | |
| 650 | 4 | |a SARS-CoV-2 (Severe Acute Respiratory Syndrome Voronavirus 2) | |
| 700 | 1 | |a Wang, S Y |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, C |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, F S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology |d 1998 |g 28(2020), 6 vom: 20. Juni, Seite 523-527 |w (DE-627)NLM096493321 |x 1007-3418 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2020 |g number:6 |g day:20 |g month:06 |g pages:523-527 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3760/cma.j.cn501113-20200416-00190 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2020 |e 6 |b 20 |c 06 |h 523-527 | ||